化学療法誘発性末梢神経障害治療市場：治療タイプ、投与経路、患者年齢層、治療期間、エンドユーザー別-2025～2030年の世界予測

化学療法誘発性末梢神経障害治療市場の2024年の市場規模は9億8,584万米ドルで、2025年には10億6,412万米ドルに成長し、CAGRは8.21%、2030年には15億8,361万米ドルに達すると予測されています。

化学療法誘発性末梢神経障害（CIPN）は、がん治療を受けている患者のQOLに影響を与える重要な課題です。この包括的な概要では、CIPN治療の現状を調査し、進化する実践と革新的な研究がいかに治療アプローチを再構築しつつあるかを明らかにします。薬理学的治療と非薬理学的治療の両方に対する微妙な理解の必要性は、かつてないほど高まっています。本レポートは、豊富なデータと動向を統合し、治療手法、地域による市場力学、主要企業の動向、産業リーダーの戦略的意思決定を支援する実用的な提言について考察しています。

CIPN治療の研究は、患者の転帰や全体的な医療費への直接的な影響に後押しされ、活発化しています。この新しい状況において、従来の治療法と画期的な治療法の両方を取り入れることは不可欠です。新しく登場した治療法と確かな臨床データは、より患者に焦点を当てたパラダイムを推進し、その結果、確立された臨床プロトコールに革新的な戦略を統合することを後押ししています。がん領域が進化し続ける中、利害関係者は将来を見据えた視点を採用し、最新の市場洞察を活用して、治療デザインにおける現在の課題と将来の機会の両方に対処しなければならないです。

この採用では、治療情勢の変化、主要なセグメンテーションの考察、市場を定義している地域と競合力学を詳細に検討するための土台を築きました。本概要は、マクロ動向から微妙なセグメンテーション要因に至るまで幅広い分析を提示することで、CIPNセグメントにおける治療成績の向上とイノベーションの促進に必要な情報を意思決定者に提供することを目的とした戦略ガイドとしての役割を果たします。

化学療法誘発性末梢神経障害治療市場の変革

近年、CIPN管理のアプローチを根本的に変える変革的な変化が起きています。化学療法とそれに続く末梢神経障害における緊急の課題は、研究開発の急増のきっかけとなり、その結果、個別化された集学的治療アプローチへの顕著な転換をもたらしました。歴史的には、CIPNは限られた標的治療による対症療法で管理されてきました。しかし、新たな研究成果と技術の進歩が統合され、より複雑な個別化治療が開発されるようになりました。

革新的な非薬剤療法は、患者の回復を促進する能力として、ますます認知されるようになってきました。鍼治療、理学療法、経皮的電気神経刺激などの手技は、従来の薬理学的手段の実行可能な代替または補完として、着実に浸透しつつあります。これらの戦略と並行して、抗けいれん薬、抗うつ薬、オピオイドなどの薬理学的治療にも焦点が当てられるようになり、有効性、安全性、患者への適合性に関する議論がさらに活発化しています。先進的な非薬剤療法と最適化された薬剤療法という二重の重点は、全人的治療の枠組みへの明確なシフトを示しています。

最近の戦略的イニシアチブはまた、がん治療の神経学的と全身的影響の両方に対処する多剤併用療法を推進することによって、ケアパスを再定義しています。臨床医は、標準化されたプロトコールのみに従うのではなく、患者固有のプロファイルに基づいて治療計画を調整するようになってきています。このような個別化されたアプローチは、薬理学的研究の飛躍的進歩や調査手法によるものであり、治療介入が科学的に確かなものであると同時に、患者中心のケアモデルに沿ったものであることを保証するものです。

さらに、デジタルヘルスツールやウェアラブル・モニタリングシステムの進化により、臨床医は治療の進捗状況をリアルタイムで追跡できるようになっています。このようなデータ主導洞察は、治療の精度を高めるだけでなく、潜在的な副作用に対するより積極的な関与を促進します。技術革新と臨床的専門知識の融合は、明らかに治療の展望を再定義し、適応的でリアルタイムな個別化された患者ケアを特徴とする新時代の到来を告げています。

CIPN治療における前進の動向は、精密医療と統合医療に向かうより広範な産業の動向を反映しています。新たなデータと先進的分析に後押しされ、医療プロバイダは、化学療法に伴う副作用に積極的に対処しながら、複雑な治療レジメンに対応できるようになりました。このパラダイムシフトは、患者の転帰を変えるだけでなく、臨床研究と専門的実践における新たなベンチマークを設定しつつあります。

市場の差別化を促進する主要なセグメンテーション洞察

詳細なセグメンテーション分析により、CIPN治療の競合情勢と戦略的展望を形成しているいくつかの重要な側面が明らかになりました。治療タイプによる調査では、アプローチを非薬理学的カテゴリーと薬理学的カテゴリーに区別しています。非薬理学的介入では、鍼治療、理学療法、経皮的神経刺激などの治療法が、薬剤治療に伴う全身的副作用を伴わない症状管理のための代替手段を提供する能力により、重要性を増しています。これと並行して、薬理学的介入も進化を続けており、特にCIPNに関連する根本的な神経学的障害を標的とする抗けいれん薬、抗うつ薬、オピオイドの採用が増加しています。

さらに投与経路によるセグメンテーションは、治療戦略の複雑さと個別化をもたらします。従来の経口投与法はその利便性から引き続き支持されているが、筋肉内投与や静脈内投与などの非経口投与法は、迅速な治療介入を必要とする患者に的を絞った投与オプションを記載しています。局所投与もまた、全身に広く影響を及ぼすことなく局所的な緩和をもたらし、治療プロトコルの多様性を高めるという重要な役割を果たしています。このような投与経路の詳細な検討は、有効性と安全性の両方を最適化する患者固有の方法を提供するというコミットメントを強調するものです。

さらに、患者の年齢層によるセグメンテーションは、成人、高齢者、小児を明確に区別しています。このような人口統計学的なセグメンテーションは、年齢に関連した生理学的な違いから、代謝、耐性、患者の回復力全体を考慮したカスタマイズ型アプローチが必要となるため、不可欠です。患者のプロファイルは千差万別であるため、このセグメンテーションの枠組みは年齢に応じた治療法の開発を促し、より洗練された臨床ガイドラインの必要性を強調するものです。

もう一つの重要な次元は治療期間であり、介入を長期療法と短期療法に分類しています。このセグメンテーションにより、個々の患者が治療期間中に必要とするケアの持続性と強度が明確になります。戦略的洞察により、慢性的または難治性の症状を持つ患者には長期的な治療ソリューションが重要である一方、急性期の管理シナリオでは短期的な治療が効果的であることが明らかになりました。こうした時間的なニュアンスを理解することで、利害関係者はリソースをより適切に配分し、患者のニーズと臨床結果に沿った治療レジメンを設計することができます。

最後に、在宅ケア、病院、専門クリニックなど、エンドユーザー設定による差別化により、ケア環境に基づいた介入のカスタマイズが可能になります。管理された病院環境で成功裏に実施された治療が、在宅ケアや専門外来クリニックに適応される際には調整が必要になる場合があります。このようなセグメンテーション洞察は、市場のポジショニング、リソースの配分、ネットワークの連携に関する戦略的意思決定に深く役立ちます。このようにセグメンテーションを重層的に行うことで、治療戦略が広範な臨床目標を満たすだけでなく、異質な患者集団の多様なニーズにきめ細かく対応できるようになります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的にがんの罹患率が上昇
    • 医療従事者の間で化学療法誘発性末梢神経障害に関する認識が高まっている
    • 世界中で腫瘍学調査への政府資金が急増
  • 抑制要因
    • 医薬品開発プロセスと研究開発活動にかかる高コスト
  • 機会
    • 末梢神経障害の症状を呈する患者に合わせた人間工学に基づいたウェアラブルの開発
    • 神経障害リスク評価の予測モデル開発におけるAI技術の活用拡大
  • 課題
    • 化学療法後の治療における神経障害メカニズムの複雑さ
• 市場セグメンテーション分析
  • 治療タイプ：神経活動を安定させるという二重の機能を持つ抗けいれん薬と抗うつ薬が好まれる傾向が高まっている
  • エンドユーザー：病院におけるCIPNの利用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 化学療法誘発性末梢神経障害治療市場：治療タイプ別

• イントロダクション
• 非薬剤療法
  • 鍼
  • 理学療法
  • 経皮的電気神経刺激
• 薬剤療法
  • 抗けいれん薬
  • 抗うつ薬
  • オピオイド

第7章 化学療法誘発性末梢神経障害治療市場：投与経路別

• イントロダクション
• 経口
• 非経口
  • 筋肉内
  • 静脈内
• 局所

第8章 化学療法誘発性末梢神経障害治療市場：患者年齢層別

• イントロダクション
• 成人
• 高齢者
• 小児

第9章 化学療法誘発性末梢神経障害治療市場：治療期間別

• イントロダクション
• 長期治療
• 短期療法

第10章 化学療法誘発性末梢神経障害治療市場：エンドユーザー別

• イントロダクション
• 在宅ケア
• 病院
• 専門クリニック

第11章 南北アメリカの化学療法誘発性末梢神経障害治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の化学療法誘発性末梢神経障害治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの化学療法誘発性末梢神経障害治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• AlgoTherapeutix
• Amgen Inc.
• Array BioPharma Inc. by Pfizer Inc.
• Artelo Biosciences, Inc.
• Asahi Kasei Corporation
• Astellas Pharma Inc.
• Bexion Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Eisai Inc.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Ltd.
• Grunenthal GmbH
• Heron Therapeutics, Inc.
• Ipsen Pharma
• Kyowa Kirin Co., Ltd.
• Merck & Co., Inc.
• Neuralace Medical
• Novartis AG
• Regenacy Pharmaceuticals LLC
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Serpin Pharma, LLC
• Takeda Pharmaceutical Company Limited
• Veloxis Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET MULTI-CURRENCY
• FIGURE 2. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET MULTI-LANGUAGE
• FIGURE 3. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH PROCESS
• FIGURE 4. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 63. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 64. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 66. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 67. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 68. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 97. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 98. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 105. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 106. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 108. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 109. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 110. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 113. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 114. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 116. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 117. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 118. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 121. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 122. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 129. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 130. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 137. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 138. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 145. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 146. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 153. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 154. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 168. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 169. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 170. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 176. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 177. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 178. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 185. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 186. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 200. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 201. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 202. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 203. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 210. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 211. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 218. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 219. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 225. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 226. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 227. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 232. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 233. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 234. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 235. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 240. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 241. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 242. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 243. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 248. ITALY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TR

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at USD 985.84 million in 2024 and is projected to grow to USD 1,064.12 million in 2025, with a CAGR of 8.21%, reaching USD 1,583.61 million by 2030.

Chemotherapy induced peripheral neuropathy (CIPN) represents a significant challenge that impacts the quality of life for patients undergoing cancer treatments. In this comprehensive summary, we explore the current state of CIPN treatment, underlining how evolving practices and innovative research are reshaping therapeutic approaches. The need for a nuanced understanding of both pharmacological and non-pharmacological treatments has never been greater. This report synthesizes a wealth of data and trends, examining treatment methodologies, regional market dynamics, key company players, and actionable recommendations that support strategic decision-making among industry leaders.

Research into CIPN treatment has intensified, propelled by its direct impact on patient outcomes and overall cost-of-care considerations. In this new landscape, embracing both traditional and breakthrough treatment modalities is essential. Newly emerging therapeutic practices and robust clinical data are driving a more patient-focused paradigm which, in turn, bolsters the integration of innovative strategies into established clinical protocols. As the oncology field continues to evolve, stakeholders must adopt a forward-looking perspective and leverage the latest market insights to address both current challenges and future opportunities in treatment design.

This introduction lays the groundwork for an in-depth examination of the transformative shifts in the treatment landscape, key segmentation insights, and regional as well as corporate competitive dynamics that are defining the market. By presenting an analysis that spans from macro trends to nuanced segmentation factors, this summary serves as a strategic guide designed to empower decision-makers with the intelligence necessary to enhance treatment outcomes and foster innovation in the field of CIPN.

Transformative Shifts in the CIPN Treatment Landscape

Recent years have witnessed transformative shifts that are fundamentally altering the approach to CIPN management. Acute challenges in chemotherapy and subsequent peripheral neuropathy have catalyzed a surge in research and development, resulting in a notable transition towards personalized and multi-disciplinary treatment approaches. Historically, CIPN was managed largely through symptomatic relief with limited targeted therapies. However, the integration of emerging research findings and technological advancements has led to the development of more intricately tailored interventions.

Innovative non-pharmacological treatments have become increasingly recognized for their ability to enhance patient recovery. Techniques such as acupuncture, physical therapy, and transcutaneous electrical nerve stimulation are steadily gaining ground as viable alternatives or complements to conventional pharmacological measures. Alongside these strategies, a refined focus on pharmacological treatments including anticonvulsants, antidepressants, and opioids has stimulated further debate on efficacy, safety, and patient suitability. The dual emphasis on advanced non-drug modalities and optimized drug regimens marks a clear shift towards a holistic treatment framework.

Recent strategic initiatives have also redefined care pathways by promoting multi-modal therapies that address both the neurological and systemic implications of cancer treatments. Clinicians are increasingly tailoring treatment plans based on a patient's unique profile rather than adhering solely to a standardized protocol. This individualized approach draws on breakthroughs in pharmacological research as well as rehabilitative practices, ensuring that therapeutic interventions are both scientifically sound and aligned with patient-centric care models.

Furthermore, the evolution of digital health tools and wearable monitoring systems is enabling clinicians to track treatment progress in real time. This data-driven insight not only enhances therapeutic precision but also fosters a more proactive engagement with potential side effects. The blend of technological innovation with clinical expertise is clearly redefining the treatment landscape and heralding a new era marked by adaptive, real-time, and individualized patient care.

The forward momentum in CIPN treatment reflects a broader industry trend towards precision medicine and integrated care. Empowered by emerging data and advanced analytics, healthcare providers are now better positioned to navigate the complexities of treatment regimens while proactively addressing the adverse effects associated with chemotherapy. This paradigm shift is not only transforming patient outcomes, but also setting new benchmarks in clinical research and professional practice.

Key Segmentation Insights Driving Market Differentiation

An in-depth segmentation analysis reveals several critical dimensions that are shaping the competitive and strategic landscape of CIPN treatment. The investigation based on treatment type distinguishes approaches into non-pharmacological and pharmacological categories. Within non-pharmacological interventions, modalities such as acupuncture, physical therapy, and transcutaneous electrical nerve stimulation demonstrate growing prominence due to their ability to offer alternative avenues for symptom management without the systemic side effects often associated with drug treatments. In parallel, pharmacological interventions continue to evolve, particularly with the increasing adoption of anticonvulsants, antidepressants, and opioids that target the underlying neurological disruptions associated with CIPN.

Further segmentation based on the route of administration introduces an added layer of complexity and personalization in treatment strategies. Traditional oral delivery methods continue to be favored for their convenience, while parenteral routes, including intramuscular and intravenous administration, provide targeted delivery options for patients requiring swift therapeutic intervention. Topical applications also play a vital role by offering localized relief without a broad systemic impact, thereby enhancing the versatility of treatment protocols. This detailed exploration of administration routes underscores the commitment to delivering patient-specific methods that optimize both efficacy and safety.

In addition, the segmentation based on patient age group illustrates a distinct differentiation among adults, geriatrics, and pediatrics. Such demographic segmentation is essential since age-related physiological differences necessitate customized approaches that account for metabolism, tolerance, and overall patient resilience. As patient profiles vary widely, this segmentation framework encourages the development of age-appropriate therapies and highlights the need for more refined clinical guidelines.

Another key dimension is therapy duration, which categorizes interventions into long-term and short-term therapies. This segmentation dimension offers clarity on the sustainability and intensity of care that individual patients may require over the course of their treatment journeys. Strategic insights reveal that long-term therapy solutions are crucial for patients with chronic or refractory symptoms, while short-term therapies are effective in acute management scenarios. By understanding these temporal nuances, stakeholders can better allocate resources and design treatment regimens that align with patient needs and clinical outcomes.

Lastly, differentiation based on the end-user setting, which encompasses home care settings, hospitals, and specialty clinics, allows for the customization of interventions based on the care environment. Treatments that are successfully delivered in a controlled hospital environment may require adjustments when adapted for home care or specialized outpatient clinics. These segmentation insights deeply inform strategic decisions related to market positioning, resource allocation, and network collaborations. Collectively, this layered segmentation approach ensures that treatment strategies not only meet broad clinical objectives but are also finely tuned to the diverse needs of a heterogeneous patient population.

Based on Treatment Type, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Acupuncture, Physical Therapy, and Transcutaneous Electrical Nerve Stimulation. The Pharmacological Treatments is further studied across Anticonvulsants, Antidepressants, and Opioids.

Based on Route of Administration, market is studied across Oral, Parenteral, and Topical. The Parenteral is further studied across Intramuscular and Intravenous.

Based on Patient Age Group, market is studied across Adults, Geriatrics, and Pediatrics.

Based on Therapy Duration, market is studied across Long-Term Therapy and Short-Term Therapy.

Based on End-User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics.

Regional Insights: Market Trends Across Key Geographies

An examination of the global landscape reveals that regional trends are central to understanding the evolving market dynamics in CIPN treatment. In the Americas, robust healthcare infrastructure and active investment in cutting-edge research form the bedrock of patient care innovation, driving a substantial uptake of both pharmacological and non-pharmacological treatments. The region's commitment to integrating novel clinical interventions with traditional treatment paradigms has set a benchmark in patient-centered care.

Across Europe, the Middle East and Africa, market dynamics are deeply influenced by ongoing regulatory reforms and increasing investments in medical research. The collaboration between regional academic institutions and healthcare providers is fostering a progressive environment that supports innovative clinical practices. The emphasis on comprehensive patient management through diversified therapeutic channels, along with the modernization of healthcare delivery systems, is markedly impacting clinical outcomes.

Asia-Pacific continues to emerge as a pivotal growth driver with a strong focus on rapid technological adoption and customized healthcare solutions. Increasing public and private investments in state-of-the-art medical infrastructure are catalyzing the development of advanced treatment practices that cater to the unique needs of its diverse population. Market trends in this region underscore a significant commitment to research, as well as the integration of digital health solutions, which is facilitating a seamless blend of traditional and innovative treatment methodologies.

The regional analysis elucidates the need for localized strategies that account for both economic and cultural factors. Each geographic zone offers distinct opportunities and challenges, thereby necessitating tailored approaches that respect local market conditions while leveraging global clinical insights. Industry stakeholders can draw on these regional insights to optimize growth strategies, enhance clinical collaborations, and ultimately, advance the overall standard of care in CIPN treatment.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape: Evaluating Key Industry Players

Within the competitive landscape, several key companies have emerged as frontrunners in CIPN treatment innovation. These industry leaders, including AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., and Asahi Kasei Corporation, have been instrumental in propelling the research, development, and commercialization of breakthrough therapeutic solutions. Further contributions come from Astellas Pharma Inc., Bexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Eisai Inc., all of which have demonstrated a steadfast commitment to advancing clinical care in this arena.

Other notable players such as F. Hoffmann-La Roche Ltd and GlaxoSmithKline PLC have leveraged extensive research and robust global networks to introduce both innovative drug compounds and supportive non-pharmacological interventions. The strategic initiatives pursued by Glenmark Pharmaceuticals Ltd., Grunenthal GmbH, and Heron Therapeutics, Inc. have provided additional momentum to the market by focusing on patient-centric treatment design and precision medicine approaches. Ipsen Pharma, Kyowa Kirin Co., Ltd., and Merck & Co., Inc. also play pivotal roles, leveraging cutting-edge research to enhance the efficacy of existing treatment paradigms.

Contributions from Neuralace Medical, Novartis AG, Regenacy Pharmaceuticals LLC, and Regeneron Pharmaceuticals, Inc. further underscore the importance of cross-collaborative efforts in addressing complex clinical challenges. Leading international pharmaceutical companies such as Sanofi S.A., Serpin Pharma, LLC, Takeda Pharmaceutical Company Limited, and Veloxis Pharmaceuticals, Inc. are also key players, with their rigorous research and adaptive clinical strategies helping to shape the future of CIPN treatment. The strategic interplay between these companies is fostering a dynamic ecosystem that continuously refines treatment protocols, enhances patient outcomes, and promotes sustainable clinical innovation across the global market.

The report delves into recent significant developments in the Chemotherapy Induced Peripheral Neuropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Bexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eisai Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Grunenthal GmbH, Heron Therapeutics, Inc., Ipsen Pharma, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Neuralace Medical, Novartis AG, Regenacy Pharmaceuticals LLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Serpin Pharma, LLC, Takeda Pharmaceutical Company Limited, and Veloxis Pharmaceuticals, Inc.. Actionable Recommendations for Industry Leaders

Leaders in the healthcare and pharmaceutical sectors are advised to adopt a multi-faceted strategic approach to navigate the evolving CIPN treatment landscape effectively. One recommendation is to invest in robust research and development initiatives that blend groundbreaking clinical trials with real-world evidence. By supporting translational research, organizations can bridge the gap between innovative theory and practical application, thereby ensuring that novel therapies are both effective and accessible.

Another key recommendation is to foster strong partnerships between academic institutions, research organizations, and clinical practitioners. Collaborative efforts that unite diverse areas of expertise can provide the synergies necessary to propel the development of both pharmacological and non-pharmacological treatment options. Furthermore, digitization and advanced data analytics should be embraced to facilitate patient-specific treatment planning, monitor outcomes more accurately, and drive continuous process improvements across the care continuum.

Industry leaders should also consider adopting flexible regulatory strategies that allow for quicker adaptation to new clinical data and technological advancements. Proactive engagement with regulatory bodies can smooth the path to market for emerging therapies, ensuring that groundbreaking treatments reach patients with minimal delays. Additionally, an emphasis on market education and awareness, through initiatives that communicate the benefits and limitations of different treatment modalities, can help healthcare providers integrate new approaches into mainstream clinical practice more seamlessly.

Finally, it is critical to allocate sufficient resources towards enhancing cross-functional expertise within organizations. By cultivating teams that are well-versed in both clinical and commercial aspects, companies can better anticipate market shifts, tailor strategies to evolving patient needs, and ultimately drive long-term value creation. Industry leaders are encouraged to evaluate their current portfolios, reassess strategic priorities, and invest in innovation centers that can serve as incubators for next-generation therapeutic solutions.

Comprehensive Summary and Forward-Looking Perspective

In summary, the analysis presented in this report highlights the multifaceted and evolving nature of CIPN treatment. From the integration of novel non-pharmacological techniques to the advancement of pharmacological interventions, the landscape is clearly defined by a dynamic interplay between innovation and patient-centered care. Detailed segmentation analysis across treatment types, routes of administration, patient age groups, therapy duration, and end-user settings articulates how personalized and adaptable care models are essential for addressing the challenges inherent in managing chemotherapy induced peripheral neuropathy.

Regional insights further cement the role of localized strategies in maximizing treatment efficacy across distinct geographic markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. These regions not only embody diverse healthcare ecosystems but also offer unique opportunities for customization and sustainable growth. Furthermore, the competitive landscape-bolstered by the innovative efforts of leading companies such as AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., Asahi Kasei Corporation, and other industry giants-reinforces the importance of cross-collaborative research and strategic partnerships in propelling the future of CIPN treatments.

This comprehensive summary provides a clear and actionable roadmap for industry stakeholders, urging them to harness the power of emerging technologies, foster collaborative research, and remain agile in the face of evolving clinical demands. The confluence of meticulous segmentation insights, regional market dynamics, and corporate innovations collectively serves as a testament to the sector's potential to transform patient care and chart new territories in the treatment of chemotherapy induced peripheral neuropathy.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer globally
    • 5.1.1.2. Growing awareness about chemotherapy induced peripheral neuropathy among healthcare providers
    • 5.1.1.3. Surge in government funding for oncology research worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of drug development processes and research and development activities
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of ergonomic wearables tailored to patients experiencing peripheral neuropathy symptoms
    • 5.1.3.2. Expanding AI technology utilization in developing predictive models for neuropathy risk assessment
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities in neuropathic mechanisms for treatment post-chemotherapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Increasing preferences for anticonvulsants and antidepressants due to their dual function in stabilizing nerve activity
  • 5.2.2. End User: Expanding utilization of CIPN in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Non-Pharmacological Treatments
  • 6.2.1. Acupuncture
  • 6.2.2. Physical Therapy
  • 6.2.3. Transcutaneous Electrical Nerve Stimulation
• 6.3. Pharmacological Treatments
  • 6.3.1. Anticonvulsants
  • 6.3.2. Antidepressants
  • 6.3.3. Opioids

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral
  • 7.3.1. Intramuscular
  • 7.3.2. Intravenous
• 7.4. Topical

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Age Group

• 8.1. Introduction
• 8.2. Adults
• 8.3. Geriatrics
• 8.4. Pediatrics

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Therapy Duration

• 9.1. Introduction
• 9.2. Long-Term Therapy
• 9.3. Short-Term Therapy

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by End-User

• 10.1. Introduction
• 10.2. Home Care Settings
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. NYU Pain Research Center Receives NIH Grant to study chemotherapy-related pain
  • 14.3.2. FDA cleared Artelo Biosciences' IND application for ART26.12
  • 14.3.3. Serpin Pharma and HekaBio's strategic partnership centers on developing SP163M
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AlgoTherapeutix
• 3. Amgen Inc.
• 4. Array BioPharma Inc. by Pfizer Inc.
• 5. Artelo Biosciences, Inc.
• 6. Asahi Kasei Corporation
• 7. Astellas Pharma Inc.
• 8. Bexion Pharmaceuticals, Inc.
• 9. Bristol-Myers Squibb Company
• 10. Eisai Inc.
• 11. F. Hoffmann-La Roche Ltd
• 12. GlaxoSmithKline PLC
• 13. Glenmark Pharmaceuticals Ltd.
• 14. Grunenthal GmbH
• 15. Heron Therapeutics, Inc.
• 16. Ipsen Pharma
• 17. Kyowa Kirin Co., Ltd.
• 18. Merck & Co., Inc.
• 19. Neuralace Medical
• 20. Novartis AG
• 21. Regenacy Pharmaceuticals LLC
• 22. Regeneron Pharmaceuticals, Inc.
• 23. Sanofi S.A.
• 24. Serpin Pharma, LLC
• 25. Takeda Pharmaceutical Company Limited
• 26. Veloxis Pharmaceuticals, Inc.